Immunotherapy / PD-1 inhibitor + Cholesterol absorption inhibitorPhase 3 trialInvestigational
Durvalumab/ezetimibe
How it works
Durvalumab is a monoclonal antibody that blocks the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells. Ezetimibe is a cholesterol absorption inhibitor that can help to reduce the side effects of durvalumab.
Cancer types
Pancreatic Cancer— All patients
Efficacy
In clinical trials, durvalumab and ezetimibe improved overall survival in patients with pancreatic cancer, with a median survival of around 11.3 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.